# Mazdutide

> GLP-1/glucagon dual agonist in Phase 3 development.

Source: https://peptides.cafe/peptide/tirzepatide-mounjaro
Category: Metabolic · Incretin
Tag: Weight loss

## Mechanism
A dual agonist of GLP-1 and glucagon receptors, similar to survodutide. The glucagon component increases energy expenditure while GLP-1 suppresses appetite and improves glycemic control.

## Research areas
- Chronic weight management
- Type 2 diabetes
- MASH / NAFLD

## Common research protocols
- Weekly subcutaneous clinical research: Weekly dosing with dose escalation in ongoing Phase 3 trials.

## Study summaries
- "Mazdutide for obesity: Phase 2 results" — The Lancet Diabetes & Endocrinology (2024): Achieved ~15% mean weight loss at 48 weeks with manageable side effects.

## Considerations
- Investigational; not FDA-approved.
- Glucagon agonism may affect heart rate and blood pressure.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.